Evidence map›Paper›PMID 35268550›Full record

ArticleJournal of clinical medicine2022

Safety of Obtaining an Extra Biobank Kidney Biopsy Core.

Sheila Bermejo, Clara García-Carro, Richard Mast, Ander Vergara, Irene Agraz, Juan Carlos León, Monica Bolufer, Maria-Alejandra Gabaldon, Daniel Serón, Oriol Bestard and 1 more

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sheila BermejoNephrology Department, Hospital de Vall d'Hebron, 08035 Barcelona, Spain.ORCID 0000-0002-3611-4830
Clara García-CarroNephrology Department, Hospital Clínico San Carlos, 28940 Madrid, Spain.
Richard MastRadiology Department, Hospital de Vall d'Hebron, 08035 Barcelona, Spain.
Ander VergaraNephrology Department, Hospital de Vall d'Hebron, 08035 Barcelona, Spain.ORCID 0000-0003-1926-0147
Irene AgrazNephrology Department, Hospital de Vall d'Hebron, 08035 Barcelona, Spain.ORCID 0000-0002-4223-6834
Juan Carlos LeónNephrology Department, Hospital de Vall d'Hebron, 08035 Barcelona, Spain.
Monica BoluferNephrology Department, Hospital de Vall d'Hebron, 08035 Barcelona, Spain.
Maria-Alejandra GabaldonPathology Department, Hospital de Vall d'Hebron, 08035 Barcelona, Spain.
Daniel SerónNephrology Department, Hospital de Vall d'Hebron, 08035 Barcelona, Spain.ORCID 0000-0003-2054-653X
Oriol BestardNephrology Department, Hospital de Vall d'Hebron, 08035 Barcelona, Spain.
Maria Jose SolerNephrology Department, Hospital de Vall d'Hebron, 08035 Barcelona, Spain.ORCID 0000-0003-3621-0766

Funding

RED INVESTIGACIÓN RENAL REDINREN, RD16/0009/0030
6 · The paper itself

Abstract

BACKGROUND AND

objectivesKidney biopsy (KB) is the "gold standard" for the diagnosis of nephropathies and it is a diagnostic tool that presents a low rate of complications. Nowadays, biobank collections of renal tissue of patients with proven renal pathology are essential for research in nephrology. To provide enough tissue for the biobank collection, it is usually needed to obtain an extra kidney core at the time of kidney biopsy. The objective of our study is to evaluate the complications after KB and to analyze whether obtaining an extra core increases the risk of complications. MATERIAL AND

methodsProspective observational study of KBs performed at Vall d'Hebron Hospital between 2019 and 2020. All patients who accepted to participate to our research biobank of native kidney biopsies were included to the study. Clinical and laboratory data were reviewed and we studied risk factors associated with complications.

resultsA total of 221 patients were included, mean age 56.6 (±16.8) years, 130 (58.8%) were men, creatinine was 2.24 (±1.94) mg/dL, proteinuria 1.56 (0.506-3.590) g/24 h, hemoglobin 12.03 (±2.3) g/dL, INR 0.99 (±0.1), and prothrombin time (PT) 11.86 (±1.2) s. A total of 38 patients (17.2%) presented complications associated with the procedure: 13.1% were minor complications, 11.3% (

conclusionsKB is an invasive and safe procedure with a low percentage of complications. Obtaining an extra kidney core for research does not increase the risk of complications during the intervention, which remains low in concordance with previously published reports.

Indexed as

biobankchronic kidney diseasecomplicationskidney biopsy

Identifiers

PMID35268550
PMCPMC8911133

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.